Autor: "Sarker SJ" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Incidence of hemorrhagic stroke in black Caribbean, black African, and white populations: the South London stroke register, 1995-2004.
Autorzy :: Smeeton NC
Heuschmann PU
Rudd AG
McEvoy AW
Kitchen ND
Sarker SJ
Wolfe CDA
Smeeton, Nigel C
Heuschmann, Peter U
Rudd, Anthony G
McEvoy, Andrew W
Kitchen, Neil D
Sarker, Shah Jalal
Wolfe, Charles D A; Pokaż więcej
Źródło :: Stroke (00392499); Dec2007, Vol. 38 Issue 12, p3133-3138, 6p
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Measuring quality of life in people living with and beyond cancer in the UK.
Autorzy :: Moschopoulou E; Institute of Population Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Deane J; Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Newcastle upon Tyne, NE2 4AX, UK.
Duncan M; Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Ismail SA; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK.
Moriarty S; Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Sarker SJ; Research Department of Medical Education, UCL Medical School, UCL, London, UK.
White P; Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Korszun A; Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. .; Pokaż więcej
Corporate Authors :: SURECAN Development Grant investigators
Źródło :: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Mar 30. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: What Is the Best Option for Treating Venous Leg Ulcer Infection? Is It Systemic or Local Antimicrobials or a Combination of Both? A Retrospective Cohort Study.
Autorzy :: Abdulhamid AK; University of Kerbala, Kerbala, Iraq.
Khalaf RJ; Alhussain Teaching Hospital, Kerbala, Iraq.
Sarker SJ; UCL Medical School, London, UK.; Pokaż więcej
Źródło :: The international journal of lower extremity wounds [Int J Low Extrem Wounds] 2021 Jan 22, pp. 1534734620980850. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Autorzy :: Shamash J; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Mee M; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Sarker SJ; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Wilson P; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Ansell W; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Greenwood M; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Berney D; Department of Histopathology, St Bartholomew's Hospital, London, UK.
Alifrangis C; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.; Department of Medical Oncology, University College London Hospital, London, UK.; Pokaż więcej
Źródło :: BJU international [BJU Int] 2020 Jun; Vol. 125 (6), pp. 843-852. Date of Electronic Publication: 2020 May 04.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents/*administration & dosage
Brain Neoplasms/*drug therapy
Neoplasms, Germ Cell and Embryonal/*drug therapy
Testicular Neoplasms/*drug therapy
Adolescent ; Adult ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Brain Neoplasms/diagnosis ; Brain Neoplasms/mortality ; Humans ; Male ; Middle Aged ; Neoplasms, Germ Cell and Embryonal/diagnosis ; Neoplasms, Germ Cell and Embryonal/mortality ; Neoplasms, Germ Cell and Embryonal/pathology ; Prognosis ; Retrospective Studies ; Testicular Neoplasms/diagnosis ; Testicular Neoplasms/mortality ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer.
Autorzy :: Smith K; Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
Galazi M; Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
Openshaw MR; Department of Medical Oncology, Charing Cross Hospital, Imperial College NHS Trust, London, UK.
Wilson P; Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
Sarker SJ; Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK.
O'Brien N; Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
Alifrangis C; Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK.
Stebbing J; Department of Medical Oncology, Charing Cross Hospital, Imperial College NHS Trust, London, UK.
Shamash J; Barts Cancer Institute, Saint Bartholomew's Hospital, London, UK. Electronic address: .; Pokaż więcej
Źródło :: Clinical genitourinary cancer [Clin Genitourin Cancer] 2020 Jun; Vol. 18 (3), pp. e217-e223. Date of Electronic Publication: 2019 Oct 10.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Autorzy :: Schmid P; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Barts Hospital NHS Trust, London, United Kingdom.
Abraham J; Velindre National Health Service (NHS) Trust, Cardiff, United Kingdom.
Chan S; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Wheatley D; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom.
Brunt AM; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom.
Nemsadze G; Institute of Clinical Oncology, Tbilisi, Georgia.
Baird RD; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom.
Park YH; Samsung Medical Centre, Seoul, Republic of Korea.
Hall PS; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom.
Perren T; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Stein RC; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London, London, United Kingdom.
Mangel L; Institute of Oncology, Medical University of Pécs, Pecs, Hungary.
Ferrero JM; Centre Antoine Lacassagne, Nice, France.
Phillips M; Barts Hospital NHS Trust, London, United Kingdom.
Conibear J; Barts Hospital NHS Trust, London, United Kingdom.
Cortes J; Ramon y Cajal University Hospital, Madrid, Spain.
Foxley A; AstraZeneca, Cambridge, United Kingdom.
de Bruin EC; AstraZeneca, Cambridge, United Kingdom.
McEwen R; AstraZeneca, Cambridge, United Kingdom.
Stetson D; AstraZeneca, Waltham, MA.
Dougherty B; AstraZeneca, Waltham, MA.
Sarker SJ; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Prendergast A; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
McLaughlin-Callan M; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Burgess M; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Lawrence C; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Cartwright H; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Mousa K; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Turner NC; Institute of Cancer Research, London, United Kingdom.; Royal Marsden Hospital, London, United Kingdom.; Pokaż więcej
Źródło :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Feb 10; Vol. 38 (5), pp. 423-433. Date of Electronic Publication: 2019 Dec 16.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Paclitaxel/*therapeutic use
Triple Negative Breast Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Double-Blind Method ; Female ; Humans ; Middle Aged ; PTEN Phosphohydrolase/metabolism ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Placebos ; Progression-Free Survival ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/metabolism ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrroles/administration & dosage ; Pyrroles/adverse effects ; Signal Transduction/drug effects ; Triple Negative Breast Neoplasms/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Can Waterlow score predict 30-day mortality and length of stay in acutely admitted medical patients (aged ≥65 years)? Evidence from a single centre prospective cohort study.
Autorzy :: Wang JW; Cardiology, Lister Hospital, Stevenage, UK .
Smith P; Lee Haynes Research Institute, Lister Hospital, Stevenage, UK.
Sarker SJ; Research Department of Medical Education, University College London, London, UK.
Elands S; Respiratory Medicine, Lister Hospital, Stevenage, UK.
Oliveira A; Respiratory Medicine, Lister Hospital, Stevenage, UK.
Barratt C; Borthwick Research Centre, Lister Hospital, Stevenage, UK.
Thorn C; General Surgery, Lister Hospital, Stevenage, UK.
Holme T; General Surgery, Lister Hospital, Stevenage, UK.
Lynch M; Cardiology, Lister Hospital, Stevenage, UK.; Pokaż więcej
Źródło :: BMJ open [BMJ Open] 2019 Nov 14; Vol. 9 (11), pp. e032347. Date of Electronic Publication: 2019 Nov 14.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Hospital Mortality*
Severity of Illness Index*
Length of Stay/*statistics & numerical data
Aged ; Aged, 80 and over ; Cause of Death ; Female ; Humans ; Linear Models ; Logistic Models ; Male ; Prospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; United Kingdom
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
Autorzy :: Schmid P; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.; Oncology-Clinical, Barts Health National Health Service Trust, London, United Kingdom.
Zaiss M; Praxis fuer Interdisziplinaere Onkologie, Freiburg, Germany.
Harper-Wynne C; Kent Oncology Centre, Maidstone and Tunbridge Wells National Health Service Trust, Tunbridge Wells, United Kingdom.
Ferreira M; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.
Dubey S; Oncology, Derriford Hospital, Plymouth Hospitals National Health System Trust, Plymouth, United Kingdom.
Chan S; Oncology-Clinical, Nottingham University Hospitals National Health System Trust, Nottingham, United Kingdom.
Makris A; Mount Vernon Cancer Centre, East & North Herts National Health System Trust, London, United Kingdom.
Nemsadze G; Institute of Clinical Oncology, Tbilisi, Republic of Georgia.
Brunt AM; Cancer Centre, University Hospitals of North Midlands National Health System Trust, Stoke-on-Trent, United Kingdom.
Kuemmel S; Kliniken Essen-Mitte, Essen, Germany.
Ruiz I; Hospital Universitario Sant Joan De Reus, Tarragona, Spain.
Perelló A; Hospital Son Espases, Palma, Spain.
Kendall A; Cancer Services, Great Western Hospitals National Health System Foundation Trust, Swindon, United Kingdom.
Brown J; Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, United Kingdom.
Kristeleit H; Medical Oncology, Queen Elizabeth Hospital, Woolwich, Lewisham and Greenwich National Health System Trust, London, United Kingdom.
Conibear J; Oncology-Clinical, Barts Health National Health Service Trust, London, United Kingdom.
Saura C; Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.
Grenier J; Institut Sainte Catherine, Avignon, France.
Máhr K; Zala County Hospital, Zalaegerszeg, Hungary.
Schenker M; Sf Nectarie Oncology Center Societate cu Raspundere Limitata, Craiova, Dolj, Romania.
Sohn J; Yonsei University Health System, Seoul, Republic of Korea.
Lee KS; National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea.
Shepherd CJ; Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Oelmann E; Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Sarker SJ; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Prendergast A; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Marosics P; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Moosa A; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Lawrence C; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Coetzee C; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Mousa K; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.
Cortés J; Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.; Ramon y Cajal University Hospital, Madrid, Spain.; Baselga Oncology Institute, Institute of Oncology, QuironGroup, Madrid, Spain.; Pokaż więcej
Źródło :: JAMA oncology [JAMA Oncol] 2019 Aug 29. Date of Electronic Publication: 2019 Aug 29.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: A phase II study of carboplatin AUC-10 guided by positron emission tomography-defined metabolic response in metastatic seminoma.
Autorzy :: Shamash J; Department of Medical Oncology, Barts Health NHS Trust, London, United Kingdom; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Electronic address: .
Syed R; Department of Nuclear Medicine, University College Hospitals NHS Foundation Trust, London, United Kingdom.
Sarker SJ; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Sarwar N; Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Sharma A; Department of Oncology, Hillingdon Hospitals NHS Foundation Trust, London, United Kingdom.
Mutsvangwa K; Department of Medical Oncology, Barts Health NHS Trust, London, United Kingdom.
Coetzee C; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Wilson P; Department of Medical Oncology, Barts Health NHS Trust, London, United Kingdom.
Rustin GJ; Department of Oncology, Hillingdon Hospitals NHS Foundation Trust, London, United Kingdom.; Pokaż więcej
Źródło :: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Jul; Vol. 115, pp. 128-135. Date of Electronic Publication: 2019 May 25.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Positron Emission Tomography Computed Tomography*
Antineoplastic Agents/*administration & dosage
Carboplatin/*administration & dosage
Seminoma/*drug therapy
Testicular Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Carboplatin/adverse effects ; Clinical Decision-Making ; Disease Progression ; Humans ; London ; Male ; Middle Aged ; Neoplasm Staging ; Predictive Value of Tests ; Progression-Free Survival ; Risk Assessment ; Risk Factors ; Seminoma/diagnostic imaging ; Seminoma/metabolism ; Seminoma/secondary ; Testicular Neoplasms/diagnostic imaging ; Testicular Neoplasms/metabolism ; Testicular Neoplasms/pathology ; Time Factors ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
Autorzy :: Newton C; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; University College Hospital, 235 Euston Road London, NW1 2BU, UK; University Hospitals Bristol NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8HW, UK; University of Bristol, Senate House, Tyndall Avenue, Bristol BS8 1TH, UK.
Murali K; The Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.
Ahmad A; The Wolfson Institute, CRUK Barts Cancer Centre, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK; Cancer Intelligence, Cancer Research UK, Angel Building, 407 St John Street, London EC1V 4AD, UK.
Hockings H; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Graham R; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
Liberale V; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
Sarker SJ; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; Research Department of Medical Education, UCL Medical School, Royal Free Campus, Hampstead, London NW3 2PR, UK.
Ledermann J; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
Berney DM; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Shamash J; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK.
Banerjee S; The Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.
Stoneham S; University College Hospital, 235 Euston Road London, NW1 2BU, UK.
Lockley M; Barts Health NHS Trust, West Smithfield, London, EC1A 7BE, UK; University College Hospital, 235 Euston Road London, NW1 2BU, UK; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: .; Pokaż więcej
Źródło :: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 May; Vol. 113, pp. 19-27. Date of Electronic Publication: 2019 Apr 04.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasms, Germ Cell and Embryonal/*drug therapy
Ovarian Neoplasms/*drug therapy
Adolescent ; Adult ; Aged ; Bleomycin/therapeutic use ; Chemotherapy, Adjuvant ; Child ; Cisplatin/therapeutic use ; Cohort Studies ; Dysgerminoma/drug therapy ; Dysgerminoma/pathology ; Endodermal Sinus Tumor/drug therapy ; Endodermal Sinus Tumor/pathology ; Etoposide/therapeutic use ; Female ; Gynecologic Surgical Procedures ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Grading ; Neoplasms, Germ Cell and Embryonal/pathology ; Neoplasms, Second Primary/epidemiology ; Ovarian Neoplasms/pathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology ; Progression-Free Survival ; Proportional Hazards Models ; Retrospective Studies ; Teratoma/drug therapy ; Teratoma/pathology ; Treatment Outcome ; Young Adult
SCR Protocol :: BEP protocol
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Is abdominal drainage after open emergency appendectomy for complicated appendicitis beneficial or waste of money? A single centre retrospective cohort study.
Autorzy :: Abdulhamid AK; Department of Surgery, Imam Hussein Medical City Hospital, Kerbala Medical University, Kerbala, Iraq.
Sarker SJ; UCL Medical School, UCL, Research Department of Medical Education, Room GF/664, Royal Free Campus, Hampstead, London, NW3 2PR, UK.; Pokaż więcej
Źródło :: Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2018 Nov 09; Vol. 36, pp. 168-172. Date of Electronic Publication: 2018 Nov 09 (Print Publication: 2018).
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Autorzy :: Davies JK; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Haemato-Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Hassan S; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Sarker SJ; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Besley C; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Oakervee H; Department of Haemato-Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Smith M; Department of Haemato-Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Taussig D; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Haemato-Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Gribben JG; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Haemato-Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Cavenagh JD; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Haemato-Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2018 Feb; Vol. 180 (3), pp. 346-355. Date of Electronic Publication: 2017 Oct 26.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Graft vs Leukemia Effect/*immunology
Leukemia, Myeloid, Acute/*immunology
Leukemia, Myeloid, Acute/*therapy
Myelodysplastic Syndromes/*immunology
Myelodysplastic Syndromes/*therapy
Adult ; Aged ; Female ; Graft Survival ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/etiology ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Lymphocyte Depletion ; Male ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/mortality ; Recurrence ; Remission Induction ; Transplantation Chimera ; Transplantation Conditioning/methods ; Transplantation, Homologous ; Treatment Outcome ; Virus Activation ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Patient-specific prediction of functional recovery after stroke.
Autorzy :: Douiri A; 1 Division of Health and Social Care, King's College London, London, UK.
Grace J; 1 Division of Health and Social Care, King's College London, London, UK.
Sarker SJ; 2 Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Tilling K; 3 School of Social and Community Medicine, University of Bristol, Bristol, UK.
McKevitt C; 1 Division of Health and Social Care, King's College London, London, UK.
Wolfe CD; 1 Division of Health and Social Care, King's College London, London, UK.
Rudd AG; 1 Division of Health and Social Care, King's College London, London, UK.; Pokaż więcej
Źródło :: International journal of stroke : official journal of the International Stroke Society [Int J Stroke] 2017 Jul; Vol. 12 (5), pp. 539-548. Date of Electronic Publication: 2017 Apr 25.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Precision Medicine*
Recovery of Function*
Stroke Rehabilitation*
Stroke/*diagnosis
Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Linear Models ; London ; Male ; Middle Aged ; Prognosis ; ROC Curve ; Registries ; Time Factors ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
Autorzy :: Shamash J; Centre for Experimental Cancer Medicine, Barts Cancer Institute, QMUL, London.
Sarker SJ; Centre for Experimental Cancer Medicine, Barts Cancer Institute, QMUL, London.
Huddart R; Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research, London.
Harland S; Department of Oncology, University College London Hospitals, London.
Joffe JK; Department of Oncology, Huddersfield Royal Infirmary, Huddersfield.
Mazhar D; Department of Oncology, Addenbrookes' Hospital, Cambridge.
Birtle A; Cancer Centre, Lancashire Teaching Hospitals, Preston.
White J; The Beatson West of Scotland Cancer Centre, Glasgow.
Chowdhury K; Centre for Experimental Cancer Medicine, Barts Cancer Institute, QMUL, London.
Wilson P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, QMUL, London.
Marshall MR; Centre for Experimental Cancer Medicine, Barts Cancer Institute, QMUL, London.
Vinnicombe S; School of Medicine, University of Dundee, Dundee, UK.; Pokaż więcej
Źródło :: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Jun 01; Vol. 28 (6), pp. 1333-1338.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Neoplasms, Germ Cell and Embryonal/*drug therapy
Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bleomycin/administration & dosage ; Bleomycin/adverse effects ; Child ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Humans ; Infusions, Intravenous ; Lung/diagnostic imaging ; Lung/drug effects ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasms, Germ Cell and Embryonal/pathology ; Prognosis ; Retrospective Studies ; Tomography, X-Ray Computed ; Young Adult
SCR Protocol :: BEP protocol
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function.
Autorzy :: Sarper M; Translational Cancer Discovery Team, CRUK Cancer Therapeutics Unit, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
Allen MD; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. .
Gomm J; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Haywood L; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Decock J; Cancer Research Centre, Qatar Biomedical Research Institute, Qatar Foundation, Doha, Qatar.
Thirkettle S; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Ustaoglu A; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Sarker SJ; Centre for Experimental Cancer Medicine, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Marshall J; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Edwards DR; School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK.
Jones JL; Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. .; Pokaż więcej
Źródło :: Breast cancer research : BCR [Breast Cancer Res] 2017 Mar 23; Vol. 19 (1), pp. 33. Date of Electronic Publication: 2017 Mar 23.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Carcinoma, Ductal, Breast/*genetics
Carcinoma, Ductal, Breast/*metabolism
Carcinoma, Intraductal, Noninfiltrating/*genetics
Carcinoma, Intraductal, Noninfiltrating/*metabolism
Cell Transformation, Neoplastic/*genetics
Cell Transformation, Neoplastic/*metabolism
Epithelial Cells/*metabolism
Matrix Metalloproteinase 8/*deficiency
Biomarkers, Tumor ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Intraductal, Noninfiltrating/pathology ; Cell Adhesion ; Cell Line, Transformed ; Cell Line, Tumor ; Cell Movement ; Cell Survival ; Female ; Gene Expression ; Gene Knockdown Techniques ; Humans ; Immunohistochemistry ; Integrin alpha6beta4/metabolism ; Matrix Metalloproteinase 8/genetics ; Matrix Metalloproteinase 8/metabolism ; Matrix Metalloproteinase 9/metabolism ; Paracrine Communication ; Protein Transport ; Proteolysis ; Signal Transduction ; Transforming Growth Factor beta/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors.
Autorzy :: Sarker SJ; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Smith SK; Cancer Care Research Program, Duke Clinical Research Institute, Durham, USA.
Chowdhury K; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Ganz PA; UCLA Schools of Medicine and Public Health, Jonsson Comprehensive Cancer Center , Los Angeles, USA.
Zimmerman S; School of Social Work, University of Illinois , Chicago, USA.
Gribben J; Centre for Haemato-Oncology, Barts Cancer Institute , Queen Mary University of London, London, UK.
Korszun A; Centre for Psychiatry, Wolfson Institute of Preventive Medicine, Queen Mary University of London,, London, UK. .; Pokaż więcej
Źródło :: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2017 Mar; Vol. 25 (3), pp. 739-748. Date of Electronic Publication: 2016 Nov 08.
Typ publikacji :: Journal Article
MeSH Terms :: Lymphoma, Non-Hodgkin/*mortality
Lymphoma, Non-Hodgkin/*psychology
Survivors/*psychology
Aged ; Female ; Humans ; Male ; Middle Aged ; Psychometrics ; Quality of Life/psychology ; Reproducibility of Results ; Risk Factors ; Social Support ; Surveys and Questionnaires ; United Kingdom/epidemiology ; United States/epidemiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Complications of biliary-enteric anastomoses.
Autorzy :: Kadaba RS; The Royal London Hospital, Barts Health NHS Trust , London , UK.; Queen Mary University of London , London , UK.
Bowers KA; The Royal London Hospital, Barts Health NHS Trust , London , UK.
Khorsandi S; The Royal London Hospital, Barts Health NHS Trust , London , UK.
Hutchins RR; The Royal London Hospital, Barts Health NHS Trust , London , UK.
Abraham AT; The Royal London Hospital, Barts Health NHS Trust , London , UK.
Sarker SJ; Queen Mary University of London , London , UK.
Bhattacharya S; The Royal London Hospital, Barts Health NHS Trust , London , UK.
Kocher HM; The Royal London Hospital, Barts Health NHS Trust , London , UK.; Queen Mary University of London , London , UK.; Pokaż więcej
Źródło :: Annals of the Royal College of Surgeons of England [Ann R Coll Surg Engl] 2017 Mar; Vol. 99 (3), pp. 210-215. Date of Electronic Publication: 2016 Sep 23.
Typ publikacji :: Journal Article
MeSH Terms :: Choledochostomy*
Bile Duct Diseases/*epidemiology
Common Bile Duct/*surgery
Hepatic Duct, Common/*surgery
Postoperative Complications/*epidemiology
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Ampulla of Vater ; Anastomosis, Surgical ; Anastomotic Leak/epidemiology ; Bile Duct Neoplasms/surgery ; Bile Ducts/injuries ; Biliary Tract Surgical Procedures ; Carcinoma, Pancreatic Ductal/surgery ; Cholangiocarcinoma/surgery ; Common Bile Duct Neoplasms/surgery ; Constriction, Pathologic/epidemiology ; Databases, Factual ; Female ; Humans ; Jejunostomy ; Logistic Models ; Male ; Middle Aged ; Mortality ; Multivariate Analysis ; Odds Ratio ; Pancreatic Neoplasms/surgery ; Pancreatitis, Chronic/surgery ; Retrospective Studies ; Tertiary Care Centers ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Proximal Resection Margin in Ivor-Lewis Oesophagectomy for Cancer.
Autorzy :: Qureshi YA; Department of Upper Gastrointestinal Surgery, The Royal London Hospital, London, UK. .
Sarker SJ; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.
Walker RC; Department of Upper Gastrointestinal Surgery, The Royal London Hospital, London, UK.
Hughes SF; Department of Upper Gastrointestinal Surgery, The Royal London Hospital, London, UK.; Pokaż więcej
Źródło :: Annals of surgical oncology [Ann Surg Oncol] 2017 Feb; Vol. 24 (2), pp. 569-577. Date of Electronic Publication: 2016 Aug 29.
Typ publikacji :: Journal Article
MeSH Terms :: Esophagectomy*
Margins of Excision*
Adenocarcinoma/*surgery
Carcinoma, Small Cell/*surgery
Carcinoma, Squamous Cell/*surgery
Esophageal Neoplasms/*surgery
Adenocarcinoma/pathology ; Aged ; Carcinoma, Small Cell/pathology ; Carcinoma, Squamous Cell/pathology ; Esophageal Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Survival Rate
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Autorzy :: Powles T; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Huddart RA; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Elliott T; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Sarker SJ; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Ackerman C; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Jones R; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Hussain S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Crabb S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Jagdev S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Chester J; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Hilman S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Beresford M; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Macdonald G; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Santhanam S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Frew JA; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Stockdale A; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Hughes S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Berney D; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.
Chowdhury S; Thomas Powles, Shah-Jalal Sarker, Charlotte Ackerman, and Daniel Berney, Queen Mary University of London; Simon Hughes and Simon Chowdhury, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London; Robert A. Huddart, Institute of Cancer Research, Sutton; Tony Elliott, Christie Hospital NHS Foundation Trust, Manchester; Robert Jones, University of Glasgow, Glasgow; Syed Hussain, University of Liverpool, Liverpool; Simon Crabb, University of Southampton, Southampton; Satinder Jagdev, St James's University Hospital, Leeds; John Chester, Cardiff University, Cardiff; Serena Hilman, Bristol Haematology and Oncology Centre, Bristol; Mark Beresford, Royal United Hospitals Bath, Bath; Graham Macdonald, Aberdeen Royal Infirmary, Aberdeen; Sundar Santhanam, Nottingham University Hospitals NHS Trust, Nottingham; John A. Frew, Northern Centre for Cancer Care, Newcastle upon Tyne; and Andrew Stockdale, University Hospital, Coventry, United Kingdom.; Pokaż więcej
Źródło :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Jan; Vol. 35 (1), pp. 48-55. Date of Electronic Publication: 2016 Oct 28.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Transitional Cell/*chemistry
Carcinoma, Transitional Cell/*drug therapy
ErbB Receptors/*analysis
Quinazolines/*administration & dosage
Receptor, ErbB-2/*analysis
Urinary Bladder Neoplasms/*chemistry
Urinary Bladder Neoplasms/*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Transitional Cell/secondary ; Cisplatin/administration & dosage ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Lapatinib ; Maintenance Chemotherapy ; Male ; Middle Aged ; Quinazolines/adverse effects ; Response Evaluation Criteria in Solid Tumors ; Urinary Bladder Neoplasms/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
Autorzy :: Crusz SM; Barts Cancer Institute, Queen Mary University of London, London, UK.
Tang YZ; Department of Radiology, St Bartholomews Hospital, London, UK.
Sarker SJ; Barts Cancer Institute, Queen Mary University of London, London, UK.
Prevoo W; Departments of Surgical and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kiyani I; Institute of Nuclear Medicine, University College Hospital, London, UK.
Beltran L; Department of Surgery, Whipps Cross Hospital, London, UK.
Peters J; Department of Surgery, Whipps Cross Hospital, London, UK.
Sahdev A; Department of Radiology, St Bartholomews Hospital, London, UK.
Bex A; Departments of Surgical and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK.
Gerlinger M; Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK. .; The Royal Marsden Hospital, London, UK. .; Pokaż więcej
Źródło :: BMC medicine [BMC Med] 2016 Nov 14; Vol. 14 (1), pp. 185. Date of Electronic Publication: 2016 Nov 14.
Typ publikacji :: Journal Article
MeSH Terms :: Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Carcinoma, Renal Cell/enzymology ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/pathology ; Disease Progression ; Female ; Humans ; Kidney Neoplasms/enzymology ; Kidney Neoplasms/genetics ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Prospective Studies ; Retrospective Studies ; Treatment Outcome
: Czasopismo naukowe

Szczegóły Pełny tekst

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Sarker SJ"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język